Shore Capital Stockbrokers Limited : Form 8.5 (EPT/RI) -

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
24
Shore Capital Stockbrokers Limited : Form 8.5 (EPT/RI) - NetPlay TV Plc

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code")

1.         KEY INFORMATION

(a) Name of exempt principal trader: Shore Capital Stockbrokers Ltd
(b) Name of offeror/offeree in relation to whose relevant securities this form relates:      Use a separate form for each offeror/offeree NetPlay TV Plc
(c) Name of the party to the offer with which exempt principal trader is connected: NetPlay TV Plc
(d) Date dealing undertaken: 02 February 2017
(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer? NO

2.         DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a)        Purchases and sales

Class of relevant security Purchases/ sales   Total number of securities Highest price per unit paid/received Lowest price per unit paid/received
Ordinary   Purchase Sales   854,536 403,334 8.8875p 8.95p 8.7703p 8.849p

(b)        Derivatives transactions (other than options)

Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit
           

(c)        Options transactions in respect of existing securities

(i)         Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit
               

(ii)        Exercising

Class of relevant security Product description e.g. call option Number of securities Exercise price per unit
         

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable)
         

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

3.         OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state "none"
  None  

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)  the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"
  None  
Date of disclosure: 03 February 2017
Contact name: Chris Robinson  
Telephone number: 0207 468 7952

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .  The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

OnTime's Bold Vision: Transforming Home Healthcare Admin

Updated Category News Views 7

Changing the Game for Home Healthcare Every now and then, an idea rolls in that speaks to a real need, and OnTime's push to soften the burdens of the home healthcare industry might just be one of those. Built from grassroots experience, they're dropping efforts to modernize the back-end monotony so healthcare workers can zero in on, well, healthcare. A Nose-Dive into...

Continue Reading
Image Analysis Group Unveils DYNAMIKA V.7 for Clinical Trials

Updated Category News Views 185

Introduction to DYNAMIKA V.7 by Image Analysis Group Image Analysis Group (IAG) has recently launched DYNAMIKA V.7, an advanced cloud platform tailored for clinical trial imaging. Following stringent audits and certifications, including SOC II Type I compliance and British Standards Institute (BSI) surveillance audit certification, this platform stands out in its field....

Continue Reading
Sanofi's Strategic Move to Enhance Adult Vaccination Pipeline

Updated Category News Views 95

Sanofi Strengthens Its Vaccination Portfolio Sanofi SA (NASDAQ: SNY) has made a significant step in the healthcare sector by acquiring Dynavax Technologies Corporation (NASDAQ: DVAX) for approximately $2.2 billion. This acquisition, which involves a cash purchase price of $15.50 per share, signals Sanofi's commitment to enhancing its capabilities in the adult immunization...

Continue Reading
Miral Impact Fund: A New Era for Community and Environment

Updated Category News Views 135

Introducing the Miral Impact Fund Miral has taken a significant step towards environmental stewardship and social responsibility by launching the Miral Impact Fund. This initiative, launched in partnership with the Authority of Social Contribution – Ma'an, aims to create a positive impact within communities by addressing pressing social issues while promoting...

Continue Reading
Class Action Update for Regeneron Pharmaceuticals Investors

Updated Category News Views 125

Class Action Lawsuit Overview for Regeneron Pharmaceuticals Levi & Korsinsky, LLP has announced that Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) investors should take note of a pending class action lawsuit concerning alleged securities fraud. Understanding the Class Action The lawsuit aims to recover losses for investors adversely affected by claims of fraud that...

Continue Reading